Many malignancies show increased expression of the epidermal growth factor (EGF) receptor family member ErbB3 (HER3). ErbB3 binds heregulin b-1 (HRGb1) and forms a heterodimer with other ErbB family members, such as ErbB2 (HER2) or EGF receptor (EGFR; HER1), enhancing phosphorylation of specific C-terminal tyrosine residues and activation of downstream signaling pathways. ErbB3 contains six YXXM motifs that bind the p85 subunit of phosphoinositide 3 (PI3)-kinase. Previous studies demonstrated that overexpression of ErbB3 in mammary tumor cells can significantly enhance chemotaxis to HRGb1 and overall metastatic potential. We tested the hypothesis that ErbB3-mediated PI3-kinase signaling is critical for heregulin-induced motility, and therefore crucial for ErbB3-mediated invasion, intravasation and metastasis. The tyrosines in the six YXXM motifs on the ErbB3 C-terminus were replaced with phenylalanine. In contrast to overexpression of the wildtype ErbB3, overexpression of the mutant ErbB3 did not enhance chemotaxis towards HRGb1 in vitro or in vivo. We also observed reduced tumor cell motility in the primary tumor by multiphoton microscopy, as well as a dramatically reduced ability of these cells to cross the endothelium and intravasate into the circulation. Moreover, whereas mutation of the ErbB3 C-terminus had no effect on tumor growth, it had a dramatic effect on spontaneous metastatic potential. Treatment with the PI3kinase inhibitor PIK-75 similarly inhibited motility and invasion in vitro and in vivo. Our results indicate that stimulation of the early metastatic steps of motility and invasion by ErbB3 requires activation of the PI3-kinase pathway by the ErbB3 receptor.
Many malignancies show increased expression of the epidermal growth factor (EGF) receptor family member ErbB3 (HER3). ErbB3 binds heregulin b-1 (HRGb1) and forms a heterodimer with other ErbB family members, such as ErbB2 (HER2) or EGF receptor (EGFR; HER1), enhancing phosphorylation of specific C-terminal tyrosine residues and activation of downstream signaling pathways. ErbB3 contains six YXXM motifs that bind the p85 subunit of phosphoinositide 3 (PI3)-kinase. Previous studies demonstrated that overexpression of ErbB3 in mammary tumor cells can significantly enhance chemotaxis to HRGb1 and overall metastatic potential. We tested the hypothesis that ErbB3-mediated PI3-kinase signaling is critical for heregulin-induced motility, and therefore crucial for ErbB3-mediated invasion, intravasation and metastasis. The tyrosines in the six YXXM motifs on the ErbB3 C-terminus were replaced with phenylalanine. In contrast to overexpression of the wildtype ErbB3, overexpression of the mutant ErbB3 did not enhance chemotaxis towards HRGb1 in vitro or in vivo. We also observed reduced tumor cell motility in the primary tumor by multiphoton microscopy, as well as a dramatically reduced ability of these cells to cross the endothelium and intravasate into the circulation. Moreover, whereas mutation of the ErbB3 C-terminus had no effect on tumor growth, it had a dramatic effect on spontaneous metastatic potential. Treatment with the PI3kinase inhibitor PIK-75 similarly inhibited motility and invasion in vitro and in vivo. Our results indicate that stimulation of the early metastatic steps of motility and invasion by ErbB3 requires activation of the PI3-kinase pathway by the ErbB3 receptor.
Introduction
The epidermal growth factor receptor (EGFR) family has been a major target of anti-cancer therapy development (Di Cosimo and Baselga, 2010) . Its members can contribute to a wide range of cell phenomena including proliferation, apoptosis, survival, invasion and differentiation in both normal and neoplastic cells. Members of this family include the EGFR or ErbB1, ErbB2 (Her2/neu), ErbB3 and ErbB4 (Burgess, 2008) . ErbB1 and ErbB2 have been most thoroughly studied, with a number of different inhibitors developed in hopes of identifying a treatment that will improve patient survival. However, the functions of ErbB1 and ErbB2 can be dependent upon ErbB3 expression through heterodimerization, and this dependency has repercussions for how tumors may respond to inhibitor treatment (Baselga and Swain, 2009 ). In non-small cell lung cancers that are driven by activating EGFR mutations, high ErbB3 expression is an indicator for gefitinib sensitivity (Engelman et al., 2005; Fujimoto et al., 2005) , suggesting that ErbB1/ErbB3 heterodimers may be critical oncogenic units in these tumors. Indeed the development of resistance to EGFR inhibitors in nonsmall cell lung cancers can occur through restoration of ErbB3 activation by upregulation of c-Met (Engelman et al., 2007) . In breast cancer, the ErbB2/ErbB3 heterodimer can also form a potent oncogenic unit (Holbro et al., 2003; Amin et al., 2010) . In mouse models where ErbB2 overexpression in the mammary gland drives tumor formation, ErbB3 expression and phosphorylation are upregulated (Siegel et al., 1999; Schade et al., 2007) . Increased ErbB3 expression correlates with higher hazard ratios for reduced survival of breast cancer patients (Sassen et al., 2008; Chiu et al., 2010) .
ErbB3 binds heregulin b-1 (HRGb1), but is unable to stimulate downstream signaling on its own, as it has a defective kinase domain; however, heterodimerization with another ErbB family member, such as ErbB2 or EGFR, permits tyrosine phosphorylation of the ErbB3 C-terminal domain . Downstream signaling from the ErbB receptors includes the activation of a number of pathways, including the phosphoinositide 3 (PI3)-kinase pathway. ErbB3 contains six YXXM motifs that bind the p85 subunit of PI3-kinase (Prigent and Gullick, 1994; Fiddes et al., 1998; Hellyer et al., 2001; Vijapurkar et al., 2003) , emphasizing the potential importance of ErbB3 in PI3-kinase activation. In NIH 3T3 cells, mutation of specific tyrosines in the ErbB3 C-terminus uncouples ErbB3 from PI3-kinase, with a strong effect on HRGb1-stimulated cell transformation and mitogenic responses (Hellyer et al., 2001; Vijapurkar et al., 2003) . Previous studies from our laboratory demonstrated that in MTLn3 mammary tumor cells, ErbB3 expression significantly enhances the chemotactic response and in vivo invasion towards HRGb1, as well as greatly increases metastatic potential without affecting primary tumor growth rate (Zhang et al., 2006; Hernandez et al., 2009a) . Thus, this model provides a valuable tool for examining how ErbB3 signaling affects metastatic properties beyond the enhancement of cell survival. PI3-kinase signaling via ErbB3 has the potential to modulate actin cytoskeleton rearrangement, thus influencing motility and chemotaxis (Adam et al., 1998; Chausovsky et al., 2000; Cain and Ridley, 2009) .
In this paper, we tested the hypothesis that the PI3kinase signaling pathway coupled to ErbB3 is critical for motility, and therefore crucial for invasion, intravasation and metastasis. We created a version of the human ErbB3 receptor in which all six tyrosine residues responsible for binding the p85 subunit of PI3-kinase were replaced with phenylalanine, and evaluated breast cancer cell lines stably expressing either the wild-type ErbB3 or the mutant ErbB3 receptor. Our data revealed that mutation of the PI3K binding sites blocked a number of responses that are enhanced by overexpression of wild-type ErbB3. These include enhanced chemotaxis towards HRGb1 in vitro and in vivo, increased tumor cell motility in the primary tumor and increased transendothelial migration, intravasation and metastasis. Taken together, our results demonstrate that coupling of the PI3-kinase pathway to ErbB3 is essential during the initial steps of breast cancer metastasis.
Results
The PI3-kinase binding sites are required for HRGb1stimulated ErbB3 tyrosine phosphorylation, p85 association, chemotaxis and invasion We created a version of the human ErbB3 receptor in which the tyrosines for all six YXXM motifs responsible for binding the p85 subunit of PI3-kinase were replaced with phenylalanine by site-directed mutagenesis. We then generated stable transductants of MTLn3 cells with the empty vector pLXSN (pLXSN), the wild-type human ErbB3 receptor (ErbB3WT) or the human ErbB3 receptor mutated in all six PI3-kinase binding sites (ErbB3-Mutant). Surface overexpression levels of the ErbB3WT and ErbB3-Mutant constructs were similar ( Figure 1a ). The endogenous rat ErbB3 was reduced using a rat-specific short hairpin RNA. All of the cell lines also stably expressed green fluorescent protein (GFP). To measure ErbB3-Mutant and ErbB3WT signaling activity, starved cultures were stimulated with HRGb1, and ErbB3 was immunoprecipitated from MTLn3 ErbB3WT and ErbB3-Mutant cell lysates. ErbB3 signaling activity and coupling to the PI3K pathway was assessed by measuring ErbB3 immunoprecipitates for tyrosine phosphorylation and p85a association. ErbB3 immunoprecipitates from HRGb1-stimulated ErbB3WT cells had high levels of tyrosine phosphorylation and complexed p85a, whereas ErbB3 immunoprecipitates from ErbB3-Mutant cells had very low levels of tyrosine phosphorylation and little or no associated p85a ( Figure 1b ). We then tested whether decreased signaling through PI3K had an effect on HRGb1-induced chemotaxis (Figure 1c ). ErbB3WT cells showed dramatically enhanced chemotaxis to HRGb1, compared with the control pLXSN cell line. In contrast, ErbB3-Mutant cells were similar to control cells, indicating that removal of the PI3-kinase binding sites completely block chemotactic responses driven by HRGb1. Chemotaxis in response to insulin did not show differences between ErbB3WT and ErbB3-Mutant cells ( Supplementary Figure 1 ). We also measured tumor cell invasiveness using Matrigel-coated transwells. We found that HRGb1 significantly enhanced invasiveness of ErbB3WT cells into Matrigel, whereas invasiveness of ErbB3-Mutant cells was significantly lower (Figure 1d ). In summary, these data suggest that PI3K association with ErbB3 is required for HRGb1 to induce chemotaxis and invasion.
The PI3K binding sites are required for enhancement of spontaneous metastatic potential, intravasation and lung seeding We then investigated the metastatic potential of the three tumor cell lines. Cells were injected into the mammary fat pads of severe-combined immunodeficient mice. We observed no significant differences in tumor growth and final tumor volumes between the three tumor types ( Figure 2a ). Terminal deoxynucleotidyl transferase (TdT)-mediated dUTP nick end labeling (TUNEL) (for apoptotic cells), ionized calcium binding adaptor molecule 1 (IBA-1) (for macrophages), pAKT and pERK staining did not show any differences between the tumors ( Supplementary Figures 2a-d) . Strikingly, intravasation, as measured by the number of circulating tumor cells, was significantly higher for ErbB3WT, compared with both pLXSN and ErbB3-Mutant ( Figure 2b ). However, staining for CD34 revealed that this result was not due to obvious differences in the number of blood vessels, which were the same in all tumor types ( Supplementary Figures 2e  and f ). Our results indicate that the enhancement in intravasation produced by ErbB3 is dependent upon coupling to PI3K.
Intravasation can be a rate limiting step for metastasis (Wyckoff et al., 2000) , and to test whether metastatic capability correlated with intravasation capability, hematoxylin-eosin sections of the lungs of the mice were evaluated. The lungs of mice carrying ErbB3WT tumors showed greater than 10 times more metastases ErbB3 activation of PI3-kinase for metastasis T Smirnova et al than the lungs of mice with pLXSN or ErbB3-Mutant tumors ( Figure 2c ). These results are consistent with intravasation rates regulating metastasis rates in this model. To evaluate lung-seeding ability separately from intravasation efficiency, the three cell lines were injected into the lateral tail vein of severe-combined immunodeficient mice (experimental metastasis assay). At 2 weeks post-injection, the mice were killed and hematoxylin-eosin sections of the lungs were examined for metastases. The lungs of mice injected with ErbB3WT cells had a small, but significant increase (approximately twofold) in lung-seeding efficiency, compared with the lungs of mice injected with the pLXSN and ErbB3-Mutant lines (Figure 2d ). We conclude that the PI3-kinase binding sites are required in vivo for ErbB3 enhancement of intravasation and lung seeding, with a major contribution to metastasis occurring at the intravasation step.
PI3-kinase binding sites are required for ErbB3 enhancement of in vivo motility and invasion
To examine the importance of ErbB3/PI3K for invasion in the primary tumor microenvironment, we used multiphoton microscopy to perform intravital imaging.
Intravital imaging enables visualization and quantification of the movement and orientation of fluorescent cells directly at the primary tumor without exogenously added stimulants or chemoattractants. Local motility and invasion in the primary tumor may contribute to the ability of tumor cells to locate blood vessels and to intravasate. GFP expressing lines were used in this assay, and at 33-38 days post injection into the mammary fat pad, animals were anesthetized and skin flap surgery was performed to expose the primary tumors for imaging (Wyckoff et al., 2007) . Total tumor cell motility in pLXSN, ErbB3WT and ErbB3-Mutant tumors was evaluated by analyzing multiple 30-min z-series from seven to eight tumors generated from each cell line. We found that ErbB3WT expression significantly enhanced tumor cell motility, compared with the pLXSN control (Figure 3a and Supplementary Movies 1 and 2). Importantly, expression of the ErbB3-Mutant did not enhance cell motility above the level of the control cell line.
The ErbB3WT cells were more polarized near vascular and stromal areas in the tumor, compared with ErbB3-Mutant cells. We used the length/width ratio of cells in the proximity of vessels to quantify polarization (Wyckoff et al., 2000) . There was a significant increase Figure 3b ). This is consistent with increased sensitivity to endogenous gradients of ligands, which could enhance both invasion and intravasation. We evaluated whether there was enhanced invasion in vivo in response to HRGb1 using microneedles containing Matrigel and HRGb1 inserted into the primary tumors to collect invasive cells ( Figure 3c ). ErbB3 expression had no effect on basal invasion into needles containing Matrigel alone. However, ErbB3WT tumor cells showed significantly enhanced in vivo invasion in response to a 50-nM HRGb1 over the empty vector control, whereas the mutant cells behaved like control cells. These data reveal that the ability of ErbB3 to directly couple to the PI3K pathway is essential for HRGb1's ability to stimulate in vivo invasion. To model the in vivo intravasation step, we used an in vitro transendothelial migration assay (Figure 3d ). Tumor cells alone, or mixed with macrophages, were plated on top of an endothelial monolayer and allowed to migrate through to the other side for 18 h. For all lines, very few carcinoma cells traversed the endothelium in the absence of macrophages. The addition of macrophages dramatically enhanced the ability of ErbB3WT cells to cross the endothelium, but did not increase the ability of pLXSN to cross. The ErbB3-Mutant line showed enhancement by macrophages, which was, however, significantly less than ErbB3WT cells. This is similar to the pattern of intravasation efficiency that we observed in vivo (Figure 2b ). Importantly, IBA-1 staining of primary tumors revealed the presence of macrophages in all the three tumor types ( Supplementary Figure 2b) , indicating that the defect in intravasation is not due to a difference in macrophage density in the tumor.
PI3-kinase inhibition reduces ErbB3WT chemotaxis, in vivo invasion and in vivo tumor cell motility
As an independent confirmation of the role of PI3kinase in chemotaxis and invasion of ErbB3WT cells, we used a p110a-selective PI3-K inhibitor, PIK-75. At a concentration of 200 nM, PIK-75 dramatically reduced the in vitro chemotactic response to HRGb1 (Figure 4a ) and lowered pAkt levels by B40% ( Supplementary  Figure 3) . PI3K inhibition increased Erk activity by B50%, consistently with a previously observed relief of feed-back inhibition following blockade of the PI3K/ Akt pathway Serra et al., 2011) . We then evaluated the effect of PIK-75 on invasion in vivo. Comparing microneedles containing HRGb1 alone, or HRGb1 with PIK-75 inserted into ErbB3WT tumors, significantly fewer ErbB3WT cells migrated into microneedles containing HRGb1 with PIK-75, compared with HRGb1 alone (Figure 4b ).
Of note, a 4-h treatment of cells in vitro with PIK-75 had no effect of cell viability (data not shown). We also examined the ability of systemic PIK-75 to inhibit HRGb1-induced responses at the primary tumor. Mice bearing ErbB3WT tumors were intraperitoneally injected with PIK-75 3 h before performing the in vivo ErbB3 activation of PI3-kinase for metastasis T Smirnova et al invasion assay, using microneedles containing HRGb1. Tumors in PIK-75-treated animals showed significantly reduced in vivo invasion (Figure 4c ), compared with tumors from vehicle control-treated animals, confirming the importance of the PI3K pathway in HRGb1induced responses in vivo. Interestingly, PIK-75 did not inhibit EGF-induced in vivo invasion (Supplementary Figure 4 ), supporting our hypothesis that PI3K signaling is specifically critical in HRGb1/ErbB3-driven invasion.
Next, we used the same treatment regimen and evaluated tumor cell motility by intravital imaging. PIK-75 treatment significantly reduced total tumor cell motility in ErbB3WT primary tumors (Figure 4d , also see Supplementary Movies 3 and 4). We observed that the ErbB3WT cells treated with vehicle control were more polarized near vessels in the tumor, as compared with tumor cells in mice pretreated with PIK-75. To determine whether this observation was significant, we evaluated the length/width ratio of cells in close proximity to vessels employing the same method used previously to compare the polarization of ErbB3WT and ErbB3-Mutant tumor cells. There was a significant decrease in the length/width ratio in ErbB3 tumors pretreated with the inhibitor (Figure 4e ). These effects were not due to differences in tumor cell survival, as TUNEL staining was similar in PIK-75 and vehicle-treated ErbB3WT tumors (data not shown).
Analysis of HRGb1-induced signaling in the ErbB3WT and ErbB3-Mutant cells
To provide more mechanistic insight into the pathways that are important for motility and invasion, activity of ErbB3 activation of PI3-kinase for metastasis T Smirnova et al the PI3K/Akt and the Erk pathways were measured in response to HRGb1 treatment, using phospho-specific antibodies. Cultures were stimulated with HRGb1 for various times and pAkt (T308) and pERK levels were measured in lysates from the three cell lines. There were no significant differences in the basal levels of pERK or in the HRGb1-induced pERK levels in the three cell lines (Figure 5a ), In contrast, basal pAKT levels were lower and the kinetics of HRGb1-induced Akt activation were delayed in the ErbB3-Mutant cells, in comparison with the other cell lines. ErbB3WT cells showed maximum pAKT levels by 5 min (Figure 5b and Supplementary Figure 5 ), whereas the ErbB3 mutant cells required 10-15 min to reach maximum.
We next examined whether the differential effect on signaling in ErbB3WT and ErbB3-Mutant cells was specific to HRGb1 stimulation, by evaluating pAKT and pERK after stimulation with EGF (Figures 5c and  d) , platelet-derived growth factor or with insulin-like growth factor-1 (Figure 5d ). The results show that there was no difference in pAKT or pERK levels in EGFtreated cells. Insulin-like growth factor-1 caused an increase in pAKT, not pERK, and the pAKT levels were the same in both cell lines. Finally, platelet-derived growth factor had no effect on these pathways, likely due to absence of the receptor. Thus, loss of the PI3K binding sites on ErbB3 resulted in AKT phosphorylation in response to HRGb1. ErbB3 activation of PI3-kinase for metastasis T Smirnova et al These results suggest that HRGb1's ability to cause a rapid stimulation of PI3K signaling is important for its biological activity in motility and invasion. Next, we employed an in vitro invasion assay using Matrigelcoated transwells, in combination with specific inhibitors, to investigate pathways downstream of ErbB3 in the ErbB3WT cells (Figure 5e ). We found that HRGb1-induced invasion was totally blocked by inhibition of p110a and Akt. Next, we looked at Rac1, which is downstream of PI3K, in the three cell lines. HRGb1 rapidly stimulated Rac1 activity by twofold in the ErbB3WT cells, whereas there was no induction in control and low levels in ErbB3-Mutant cells (Supplementary Figure 6) . In accordance with these results, treatment with a Rac 1 inhibitor (NSC23766) reduced invasion by approximately 50% (Figure 5e ). In contrast, treatment with a Pak inhibitor had no effect on HRGb1-induced invasion (data not shown). Taken together, the data suggest that invasion of the ErbB3WT cells is mainly dependent upon the PI3K-Akt-Rac pathway.
Discussion
In this study, we utilized the MTLn3 cell line to evaluate the role of the YXXM sites in ErbB3 in breast cancer metastasis. We find that these sites are required for ErbB3-mediated chemotactic responses to HRGb1 in vitro and invasion responses both in vitro and in vivo. Increased expression of wild-type ErbB3 had no effect on primary tumor growth, but significantly enhanced intravasation and spontaneous metastasis (Figure 2 and our previous publication (Xue et al., 2006) ). Mutation of the YXXM sites dramatically reduced the enhancement of intravasation and metastasis, whereas having no effect on primary tumor growth. In an experimental metastasis assay, wild-type ErbB3 overexpression had a significant, albeit slight, effect on the lung-seeding process, which also required ErbB3 coupling to PI3K. Similarly, an increase in spontaneous motility and cell polarization in the primary tumor induced by wild-type ErbB3 required the YXXM sites. Treatment of tumor-bearing mice with the p110a inhibitor PIK-75 caused a significant decrease in intravital motility and in vivo invasion, attesting to the important role of PI3K in invasion. Overexpression of ErbB3 in the aggressive MDA-MB-231 human breast cancer model also significantly enhanced the invasiveness of the cells in response to HRGb1 treatment ( Supplementary Figure 7) . Taken together, the data presented here indicate that the ability of ErbB3 to couple to the PI3K/Akt pathway confers tumors overexpressing this receptor, with an enhanced ability to invade and to metastasize.
On the basis of the studies reported here, we have identified intravasation as a key stage in metastasis that is enhanced by ErbB3 signaling both in vivo and in the in vitro transendothelial migration assay. Intriguingly, EGFR overexpression is not equivalent to ErbB3 ErbB3 activation of PI3-kinase for metastasis T Smirnova et al overexpression in the in vitro transendothelial migration assay, as the former do not show increased intravasation (data not shown), whereas, as we show here, ErbB3 overexpression has a positive impact. These results are consistent with our in vivo studies using EGFR inhibitors (Kedrin et al., 2009) , where we show that inhibition of EGFR had a slow inhibitory effect on intravasation and was only evident with a delay of several hours after EGFR inhibition. Conversely, inhibition of ErbB2 rapidly inhibited intravasation (Kedrin et al., 2009) . As ErbB3 forms preferred heterodimers with ErbB2, this suggests that an ErbB3/ErbB2 heterodimer is important in enhancing the intravasation step, whereas EGFR is important for tumor cell invasion from the primary tumor to reach the blood vessels (Kedrin et al., 2009) . HRGb1 is present in serum in subnanomolar concentrations (Ky et al., 2009) , and by increasing ErbB3 levels in the tumor cells, this might enable them to detect low levels of HRGb1 and increase their intravasation. Endothelial cells have also been reported to express HRGb1, which may also stimulate intravasation (Iivanainen et al., 2007; Kalinowski et al., 2010) . HRGb1 activated PI3K/Akt in both ErbB3WT and ErbB3-Mutant cells, but with different kinetics. In ErbB3WT cells, the pathway was maximally activated after 5 min of HRGb1 stimulation, whereas it took between 10 and 15 min to see the same signal intensity in the ErbB3-Mutant cells. This suggests that early pathway activation, which is dependent upon p85/PI3K binding to HRGb1-activated ErbB3-containing heterodimers, is responsible for the major effects of the ligand on migration and invasion. The fact that blockade of PI3K or Akt activity using selective inhibitors totally blocked HRGb1-induced invasion (Figure 5e ), whereas ErbB3-Mutant cells were only blocked in their invasive ability by B60% (Figure 1d ), very likely reflects the fact that the PI3K/Akt pathway does get activated in these cells, but with slower kinetics. The importance of the kinetics of signaling pathway activation in response to ErbB ligands has been observed in other systems, (Olayioye et al., 2001) .
Although previous studies have shown the direct binding of p85 and subsequent signaling from all six YXXM motifs on the ErbB3 C-terminus (Prigent and Gullick, 1994; Hellyer et al., 2001) , high-throughput methods such as protein microarray studies suggest that other molecules could bind these sites (Jones et al., 2006) . To confirm that the phenotype in the ErbB3-Mutant MTLn3 cells is due to defective PI3K pathway signaling, we used the p110a selective inhibitor PIK-75, revealing that the in vitro chemotaxis as well as in vivo invasion of MTLn3-ErbB3WT cells towards HRGb1 was impaired, following PI3K inhibition. Moreover, pretreatment of mice carrying ErbB3WT cell-induced tumors with PIK-75 caused reduced tumor cell motility, as visualized by multiphoton microscopy. Furthermore, the cells in the treated tumors were also more rounded on average as quantified by length/width ratios, thus mimicking the phenotype of the mutant ErbB3 tumors. These experiments support the hypothesis that PI3K pathway activation by ErbB3 is a major contributor to enhancing the initial steps of the metastatic cascade of mammary tumor cells.
Materials and methods

Cell culture
Rat mammary carcinoma MTLn3 cells (Neri et al., 1982) were grown in a-MEM supplemented with 5% fetal bovine serum and penicillin/streptomycin solution (Life Technologies, Rockville, MD, USA). HRGb1 was from R&D Systems (Minneapolis, MN, USA, 396-HB). MDA-MB-231 cells (American Type Culture Collection) were cultured in DMEM (Life Technologies Inc., Rockville, MD, USA) with 10% fetal bovine serum.
Animal models and in vivo assays for metastatic progression All procedures involving mice were conducted in accordance with the National Institutes of Health regulations concerning the use and care of experimental animals. The study of mice was approved by the Albert Einstein College of Medicine Animal Use Committee. MTLn3 derived cell lines were grown to a 70-85% confluence before being harvested for in vivo assays. To measure spontaneous metastasis, 5 Â 10 5 cells were detached by incubation in Dulbecco's phosphate-buffered saline þ 2 mmol/l ethylenediamine tetraacetic acid, scraping with a rubber policeman, centrifuged and resuspended in Dulbecco's phosphate-buffered saline at 10 7 cells/ml. MTLn3 (5 Â 10 5 ) cells were injected into the right fourth mammary fat pad from the head of 5-to 7-week-old female severe-combined immunodeficient/NCr mice (National Cancer Institute, Bethesda, MD, USA) in 100 ml Dulbecco's phosphate-buffered saline with calcium and magnesium (Mediatech, Manassas, VA, USA, 21-031-cv) through a 25-gauge needle. Tumor growth rate was monitored at weekly intervals by measuring in two dimensions, and tumor volumes were calculated using the formula: length Â width 2 /2. At the end point for spontaneous metastasis, the blood burden assay was performed using blood taken from the right atrium via heart puncture with a 25-gauge needle, and a 1-ml syringe coated with heparin and containing 0.1 ml of heparin. Blood was plated in tissue culture medium, and after 7 days, all tumor colonies in the dish were counted. Tumor blood burden was calculated as the total colonies in the dish divided by the volume of blood taken. To measure experimental lung metastasis, 5 Â 10 5 cells were injected into the lateral tail veins of 5-to 7-week-old female severecombined immunodeficient mice (National Cancer Institute). After 2 weeks of injection, the mice were killed, and the lungs were removed, fixed in formalin and stained hematoxylineosin sections were counted for metastasis. For each lung sample, all micrometastases were counted using a 10 Â objective. The efficiency of lung metastasis was expressed in number of metastases per lung section for each animal. Mean and s.e. were then calculated for each cell line.
In vivo invasion assay
The measurement of cell invasion into needles placed in the primary tumor of anesthetized mice was carried out, as described previously, in detail (Hernandez et al., 2009b) . Invasive cells were collected into 33-gauge Hamilton needles (Fisher, Pittsburgh, PA, USA, 14-815-423) filled with Matrigel (Beckton Dickinson, Franklin Lakes, NJ, USA, 356234) diluted 1:10 with L15-bovine serum albumin þ /À chemoattractant for 4 h. At the end of collection, the contents of the needles were extruded, using 0.5 mg/ml 4 0 ,6-diamidino-2-phenylindole in phosphate-buffered saline in a syringe, onto a coverslip. The chemoattractants used in this assay include HRGb1 at a concentration of 50 nM (R&D Systems 396-HB) and EGF at 25 nM (Life Technologies). To inhibit the activity of PI3-kinase, PIK-75 (Axon Medchem, Groningen, The Netherlands, Axon 1334), a p110a-selective inhibitor (Chaussade et al., 2007) , was used at 1 mM.
Intravital imaging
Orthotopic primary tumors were grown and imaged at 4-5 weeks post injection. The animal was anesthetized and a skin flap surgery was performed to expose the tumor. The animal was placed on an inverted microscope and tumor cells were imaged using a Radiance 2000 MP multiphoton (Zeiss, Thornwood, NY, USA), or on an Fluoview FV1000-MPE microscope (Olympus, Center Valley, PA, USA), using an excitation wavelength of 880 nm with a Â 20 0.75 NA water objective (Wyckoff et al., 2007) or a Â 25 1.05NA water objective at resolutions of 1.06 and 0.994 mm per pixel, respectively. Cell motility was observed by time-lapse imaging over 30 min at 2-min intervals, where a 100 mm z-series, with 10 mm steps, was collected at each time point. For quantification of average total cell motility, a motility event was defined as a protrusion of half-a-cell length or more. The length/width ratio (L/W) was calculated using ImageJ (Rasband, WS, US National Institutes of Health, Bethesda, MD, USA; http://imagej.nih.gov/ij/) as follows: length was scored as the Feret's diameter of the cell (the longest distance between any two points along the boundary); width was scored as the secondary axis of the best-fit ellipse of the circled cells. Cells near stromal and vascular areas of the tumor in the top 40 mm from the tumor surface were selected for these measurements. For inhibition of PI3-kinase in the tumor cells in vivo for imaging, PIK-75 was dissolved in DMSO, and 3 h prior to imaging, a dose calculated to be 50 mg/kg of body mass was mixed with 200-300 ml PBS such that the final solution consisted of no more than 20% DMSO and 20% b-cyclodextrin, and injected intraperitoneally, following a previously described procedure (Hayakawa et al., 2007) .
Additional reagents and methods are described in the Supplementary Materials and Methods.
Statistical analysis
Statistical significance was determined using unpaired, two-tailed Student's t-tests, assuming unequal variances and an a-level of 0.05. Differences were considered significant if the P-value was o0.05. For blood burden assays, the non-parametric Mann-Whitney or Wilcoxon rank sum test was used.
